Cholesterol LDL
Showing 1 - 25 of 8,036
Atherosclerotic Cardiovascular Disease, Older Patients, LDL Cholesterol Trial (Achieving a Target LDL-C level of 25mg/dL=
Not yet recruiting
- Atherosclerotic Cardiovascular Disease
- +2 more
- Achieving a Target LDL-C level of 25mg/dL≤ LDL-C<70mg/dL
- Achieving a Target LDL-C level of 70mg/dL≤ LDL-C<100mg/dL
- (no location specified)
Mar 14, 2023
Hypercholesterolemia, Dyslipidemias Trial in Hamburg (lipodia)
Not yet recruiting
- Hypercholesterolemia
- Dyslipidemias
- lipodia
-
Hamburg, GermanyGAIA AG
Aug 3, 2023
Different Equations to Accurately Calculate LDL Cholesterol
Active, not recruiting
- Dyslipidemias
- Lipid Disorder
- no intervention, Serum LDL cholesterol calculation
-
Bron, FranceLaboratoire de Biologie Médicale Multi Sites, Centre de Biologie
Oct 24, 2022
Cardiovascular Diseases Trial in Reus (Aged black garlic extract, Placebo)
Completed
- Cardiovascular Diseases
- Aged black garlic extract
- Placebo
-
Reus, Tarragona, SpainCentro Tecnológico de Nutrición y Salud (Eurecat-Reus)
Feb 25, 2022
Categories and Attaining LDL-C Targets in Middle Eastern Adults
Not yet recruiting
- Atherosclerotic Cardiovascular Risk
- Low-density-lipoprotein (LDL) Cholesterol
- (no location specified)
Feb 16, 2023
To Reduce the LDL-C Level in Hypercholesteremia Adult Patients, Combination for Subgroup High LDL-c Patients With Other
Not yet recruiting
- To Reduce the LDL-C Level in Hypercholesteremia Adult Patients
- Combination for Subgroup High LDL-c Patients With Other Comorbidities
- RN0191 INJECTION
- (no location specified)
Jun 14, 2023
Cholesterol Variability, Trained Immunity Trial (Atorvastatin)
Not yet recruiting
- Cholesterol Variability
- Trained Immunity
- (no location specified)
Mar 17, 2023
LDL-cholesterol Trial in Jena (statins, ezetimibe, bempedoic acid, evolocumab, alirocumab, inclisiran)
Recruiting
- LDL-cholesterol
- statins, ezetimibe, bempedoic acid, evolocumab, alirocumab, inclisiran
-
Jena, Thuringia, GermanyUniversity Hospital Jena
Oct 17, 2022
Cardiovascular Disease Trial in Seoul (Intensive targeting group, Conventional therapy group)
Recruiting
- Cardiovascular Disease
- Intensive targeting group
- Conventional therapy group
-
Seoul, Korea, Republic ofYonsei University Health System, Severance Hospital
Oct 7, 2022
Hypercholesterolemia, Insulin Resistance, Insulin Secretion Trial in Tuebingen (Lowering cholesterol concentrations by PCSK-9
Recruiting
- Hypercholesterolemia
- +2 more
- Lowering cholesterol concentrations by PCSK-9 inhibitor
-
Tuebingen, GermanyUniversity of Tuebingen, Department of Internal Medicine IV
Aug 24, 2022
Diabetes, Type 2, Diet, Vegetarian, Diet, Vegan Trial in Utrecht (12-week plant-based dietary program, Usual Diet)
Recruiting
- Diabetes Mellitus, Type 2
- +7 more
- 12-week plant-based dietary program
- Usual Diet
-
Utrecht, NetherlandsDepartment of Vascular Medicine UMC Utrecht
Mar 8, 2023
Cardiovascular Health Trial in Alhendín (Garlic and onion concentrate, Control)
Recruiting
- Cardiovascular Health
- Garlic and onion concentrate
- Control
-
Alhendín, Granada, SpainDomca Sau
May 20, 2022
Above Optimal Plasma LDL Concentrations Trial in Winnipeg, Toronto (muffin)
Active, not recruiting
- Above Optimal Plasma LDL Concentrations
- muffin
-
Winnipeg, Manitoba, Canada
- +1 more
Oct 24, 2022
Healthy Trial in Parma (Bergamot Juice)
Recruiting
- Healthy
- Bergamot Juice
-
Parma, ItalyUniversity of Parma, Department of Medicine and Surgery
Oct 18, 2022
Hypercholesterolemia Trial in Clermont-ferrand, Clermont-Ferrand, Durtol (LIMICOL, PLACEBO)
Completed
- Hypercholesterolemia
- LIMICOL
- PLACEBO
-
Clermont-ferrand, France
- +3 more
Feb 28, 2023
Cardiovascular Diseases Trial (Meal timing)
Recruiting
- Cardiovascular Diseases
- Meal timing
-
Bath, United KingdomDepartment for Health, University of Bath
Oct 10, 2022
Hypercholesterolemia, Hyperlipidemias, Physical Inactivity Trial in Adelaide (Egg diet, Egg-free Diet, Control Diet)
Recruiting
- Hypercholesterolemia
- +3 more
- Egg diet
- +2 more
-
Adelaide, South Australia, AustraliaUniversity of South Australia Clinical Trial Facility
Mar 1, 2022
Hyperlipidemia Trial in Changsha, Chengdu, Beijing (100 mg inclisiran sodium (equivalent to 94.5 mg inclisiran), Placebo, 300 mg
Completed
- Hyperlipidemia
- 100 mg inclisiran sodium (equivalent to 94.5 mg inclisiran)
- +2 more
-
Changsha, Hunan, China
- +2 more
Dec 2, 2021
Coronary Disease Trial (MK0653, ezetimibe / Duration of Treatment: 27 Weeks, MK0733, simvastatin / Duration of Treatment: 27
Completed
- Coronary Disease
- MK0653, ezetimibe / Duration of Treatment: 27 Weeks
- +2 more
- (no location specified)
Feb 7, 2022
Cardiovascular Diseases, Atherosclerosis, Dyslipidemias Trial (Digitally-enabled Multifaceted Quality Improvement Intervention,
Not yet recruiting
- Cardiovascular Diseases
- +2 more
- Digitally-enabled Multifaceted Quality Improvement Intervention
- Usual care
- (no location specified)
Nov 14, 2022
Hyperlipemia Trial in Beijing (RBD7022, Placebo)
Recruiting
- Hyperlipemia
- RBD7022
- Placebo
-
Beijing, Beijing, ChinaPeking Union Medical College Hospital
Jun 12, 2023
Atherosclerotic Cardiovascular Disease, Atherosclerotic Cardiovascular Disease Risk Equivelents, Elevated Low Density
Active, not recruiting
- Atherosclerotic Cardiovascular Disease
- +2 more
- Inclisiran
- Behavioural Support
-
Sale, Cheshire, United Kingdom
- +16 more
Jan 20, 2023
Hyperlipidemia Trial in Leuven (Cholesfytol NG®) supplement)
Completed
- Hyperlipidemia
- Cholesfytol NG®) supplement
-
Leuven, BelgiumCliniques universitaires St-Luc and Institut de Recherche Expéri
Aug 18, 2023
Familial Hypercholesterolaemia Trial in Czechia (Total cholesterol (TC) level test and direct Low density lipoprotein
Recruiting
- Familial Hypercholesterolaemia
- Total cholesterol (TC) level test and direct Low density lipoprotein cholesterol (LDL-C) level test
- DNA testing
-
Brno, Czechia
- +10 more
Nov 25, 2022